Clinical trial
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed…
NCT00308087 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00308087 |
|---|---|
| Title | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma |
| Official title | Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma |
| Acronym | PREMIER |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | Sargramostim (Leukine), Rituximab |
| Enrollment | 75 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Mar 29, 2006 |
| Last update posted | Dec 27, 2013 |
| Countries | Puerto Rico, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: